Recorded April 9, 2026
circRNA is reshaping RNA therapeutics but scaling it from lab to clinic requires solving real manufacturing challenges.
In this joint webinar, Circurna and uBriGene break down exactly how to get there, sharing manufacturing strategies, analytical solutions, and process innovations to advance circRNA programs toward clinical translation.
Key Topics
- circRNA’s advantages and therapeutic potential
- Manufacturing innovations shaping circRNA development
- Circularization efficiency and purity at scale
- Analytical methods for circRNA characterization
- Real-world insights from circRNA developers
In this session, Circurna and uBriGene highlight their complementary capabilities to support circRNA programs from discovery through clinical translation.
Who should watch:
Biotech leaders, CMC scientists, and manufacturing partners developing circRNA or other RNA-LNP therapeutics.
Speakers
- Scott Pattison, Ph.D.
Sr. Director of Business Development, uBriGene - Robert Rickert, Ph.D.
Chief Scientific Officer, Circurna - Jeffrey Hung, Ph.D. (Moderator)
VP of Commercial Strategy, uBriGene - Peter Weinstein, Ph.D., J.D. (Panelist)
Chief Executive Officer & Co-Founder, Circurna
Watch the full webinar